Advertisement
UK markets closed
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     
  • AIM

    755.28
    +2.16 (+0.29%)
     
  • GBP/EUR

    1.1678
    +0.0021 (+0.18%)
     
  • GBP/USD

    1.2503
    -0.0008 (-0.07%)
     
  • Bitcoin GBP

    51,199.47
    -485.67 (-0.94%)
     
  • CMC Crypto 200

    1,333.10
    -63.43 (-4.38%)
     
  • S&P 500

    5,110.17
    +61.75 (+1.22%)
     
  • DOW

    38,296.17
    +210.37 (+0.55%)
     
  • CRUDE OIL

    83.75
    +0.18 (+0.22%)
     
  • GOLD FUTURES

    2,351.10
    +8.60 (+0.37%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

1 Hot Growth Stock to Buy, and 1 to Avoid (For Now)

On that note, Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) worked together to develop and commercialize their coronavirus vaccine, Comirnaty. In BioNTech's second quarter, practically 100% of its product sales, totaling around $3.3 billion, were attributable to its share of jab revenue.